Review



osteoblast growth medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    PromoCell osteoblast growth medium
    Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional <t>osteoblasts.</t>
    Osteoblast Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 216 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osteoblast growth medium/product/PromoCell
    Average 96 stars, based on 216 article reviews
    osteoblast growth medium - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins"

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    Journal: Biomaterials Research

    doi: 10.34133/bmr.0320

    Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional osteoblasts.
    Figure Legend Snippet: Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional osteoblasts.

    Techniques Used: Recombinant, Expressing, Transduction, Functional Assay

    Direct reprogramming of HDFs into osteoblasts through ectopic overexpression of Oct4 and Cbfβ. (A) Schematic illustration of direct reprogramming process using the pCXLE episomal plasmid delivery system. The pCXLE-Oct4 and pCXLE-Cbfβ plasmids were delivered into HDFs via cationic polymer-based transfection, either individually or in combination. (B) Representative images of alkaline phosphatase (ALP) staining after 14 d of culture in osteogenic medium (OM). (C and D) Calcium deposition after 24 d of osteogenic induction, as detected by Alizarin Red S (ARS) and OsteoImage assays. (E and F) Immunofluorescence images showing expression of osteopontin (OPN) and osteocalcin (OCN), on day 24. Coexpression of Oct4 and Cbfβ induced robust expression of both osteogenic markers.
    Figure Legend Snippet: Direct reprogramming of HDFs into osteoblasts through ectopic overexpression of Oct4 and Cbfβ. (A) Schematic illustration of direct reprogramming process using the pCXLE episomal plasmid delivery system. The pCXLE-Oct4 and pCXLE-Cbfβ plasmids were delivered into HDFs via cationic polymer-based transfection, either individually or in combination. (B) Representative images of alkaline phosphatase (ALP) staining after 14 d of culture in osteogenic medium (OM). (C and D) Calcium deposition after 24 d of osteogenic induction, as detected by Alizarin Red S (ARS) and OsteoImage assays. (E and F) Immunofluorescence images showing expression of osteopontin (OPN) and osteocalcin (OCN), on day 24. Coexpression of Oct4 and Cbfβ induced robust expression of both osteogenic markers.

    Techniques Used: Over Expression, Plasmid Preparation, Polymer, Transfection, Staining, Immunofluorescence, Expressing

    Direct reprogramming of HDFs into osteoblasts using cell-permeable protein-based platform. (A) Schematic illustration of the reprogramming strategy using 30Kc19-fused recombinant proteins. HDFs were treated with a combination of Oct4-30Kc19 and Cbfβ-30Kc19 recombinant proteins 8 times over 8 d, followed by culture in OM. (B and C) ARS staining and subsequent quantification on day 24, showing robust calcium deposition in the group treated with both proteins. Data are presented as means ± SD ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. Unless otherwise indicated, comparisons were made to the nontreated control group (** P < 0.01; *** P < 0.001; ns, not significant). (D and E) Von Kossa staining and OsteoImage mineralization assay images, confirming mineralized matrix formation. Treatment with both Oct4-30Kc19 and Cbfβ-30Kc19 resulted in significantly enhanced mineralization compared with single-factor or untreated controls.
    Figure Legend Snippet: Direct reprogramming of HDFs into osteoblasts using cell-permeable protein-based platform. (A) Schematic illustration of the reprogramming strategy using 30Kc19-fused recombinant proteins. HDFs were treated with a combination of Oct4-30Kc19 and Cbfβ-30Kc19 recombinant proteins 8 times over 8 d, followed by culture in OM. (B and C) ARS staining and subsequent quantification on day 24, showing robust calcium deposition in the group treated with both proteins. Data are presented as means ± SD ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. Unless otherwise indicated, comparisons were made to the nontreated control group (** P < 0.01; *** P < 0.001; ns, not significant). (D and E) Von Kossa staining and OsteoImage mineralization assay images, confirming mineralized matrix formation. Treatment with both Oct4-30Kc19 and Cbfβ-30Kc19 resulted in significantly enhanced mineralization compared with single-factor or untreated controls.

    Techniques Used: Recombinant, Staining, Control, Mineralization Assay

    Transcriptomic remodeling toward an osteoblast lineage by Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. (A) Scatterplot showing differentially expressed genes (DEGs) between nontreated HDFs and protein-induced osteoblasts (piOBs) treated with Oct4-30Kc19 and Cbfβ-30Kc19 proteins (fold change ≥ 2). (B) Gene Ontology (GO) enrichment analysis of DEGs, highlighting overrepresentation of transcription-related biological processes. (C) Protein interaction network of enriched GO terms related to transcription regulation by RNA polymerase II. (D) Hierarchical clustering analysis of genes differentially expressed in both piOBs and primary human osteoblasts (hOBs), relative to HDFs. (E) Heatmap of DEGs associated with the ossification GO term, showing the expression of key osteogenic markers.
    Figure Legend Snippet: Transcriptomic remodeling toward an osteoblast lineage by Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. (A) Scatterplot showing differentially expressed genes (DEGs) between nontreated HDFs and protein-induced osteoblasts (piOBs) treated with Oct4-30Kc19 and Cbfβ-30Kc19 proteins (fold change ≥ 2). (B) Gene Ontology (GO) enrichment analysis of DEGs, highlighting overrepresentation of transcription-related biological processes. (C) Protein interaction network of enriched GO terms related to transcription regulation by RNA polymerase II. (D) Hierarchical clustering analysis of genes differentially expressed in both piOBs and primary human osteoblasts (hOBs), relative to HDFs. (E) Heatmap of DEGs associated with the ossification GO term, showing the expression of key osteogenic markers.

    Techniques Used: Expressing

    Efficient bone defect regeneration using a cell-permeable protein-based direct reprogramming platform. (A) Schematic illustration of the in vivo bone regeneration experiment. HDFs were pretreated 8 times with Oct4-30Kc19 and Cbfβ-30Kc19 proteins, seeded onto gelatin cryogels, and transplanted into 4-mm-sized calvarial defects in mice. Created with biorender.com . (B) Representative micro-CT 3D images showing bone regeneration 8 weeks post-transplantation. Green areas and arrows indicate newly regenerated bones, while yellow arrows denote bone defect regions. (C and D) Quantification of bone volume fraction (BV/TV) and trabecular separation in the regenerated bone tissue. Data are presented as means ± SD ( n = 4). Statistical significance was determined by Student’s t test (*** P < 0.001). (E) Hematoxylin and eosin (H&E) staining showing histological differences between defects implanted with untreated HDFs and those implanted with piOBs. (F) Masson’s trichrome (MTC) staining revealing collagen-rich new bone formation in the piOB-treated group. FT, fibrous tissues; NB, new bones. (G and H) Immunofluorescent staining for OPN and OCN, confirming the presence of mature osteoblast-derived matrix in piOB-transplanted defects.
    Figure Legend Snippet: Efficient bone defect regeneration using a cell-permeable protein-based direct reprogramming platform. (A) Schematic illustration of the in vivo bone regeneration experiment. HDFs were pretreated 8 times with Oct4-30Kc19 and Cbfβ-30Kc19 proteins, seeded onto gelatin cryogels, and transplanted into 4-mm-sized calvarial defects in mice. Created with biorender.com . (B) Representative micro-CT 3D images showing bone regeneration 8 weeks post-transplantation. Green areas and arrows indicate newly regenerated bones, while yellow arrows denote bone defect regions. (C and D) Quantification of bone volume fraction (BV/TV) and trabecular separation in the regenerated bone tissue. Data are presented as means ± SD ( n = 4). Statistical significance was determined by Student’s t test (*** P < 0.001). (E) Hematoxylin and eosin (H&E) staining showing histological differences between defects implanted with untreated HDFs and those implanted with piOBs. (F) Masson’s trichrome (MTC) staining revealing collagen-rich new bone formation in the piOB-treated group. FT, fibrous tissues; NB, new bones. (G and H) Immunofluorescent staining for OPN and OCN, confirming the presence of mature osteoblast-derived matrix in piOB-transplanted defects.

    Techniques Used: In Vivo, Micro-CT, Transplantation Assay, Staining, Derivative Assay



    Similar Products

    96
    PromoCell osteoblast growth medium
    Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional <t>osteoblasts.</t>
    Osteoblast Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osteoblast growth medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    osteoblast growth medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell osteoblast growth medium gm
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Osteoblast Growth Medium Gm, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osteoblast growth medium gm/product/PromoCell
    Average 96 stars, based on 1 article reviews
    osteoblast growth medium gm - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell ready to use osteoblasts growth medium
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Ready To Use Osteoblasts Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ready to use osteoblasts growth medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    ready to use osteoblasts growth medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell osteoblasts growth medium
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Osteoblasts Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osteoblasts growth medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    osteoblasts growth medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell growth media
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Growth Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/growth media/product/PromoCell
    Average 96 stars, based on 1 article reviews
    growth media - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell basal medium
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Basal Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/basal medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    basal medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell human osteoblast growth medium
    Glucocorticoids impair <t>osteoblast</t> function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.
    Human Osteoblast Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteoblast growth medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    human osteoblast growth medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    Image Search Results


    Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional osteoblasts.

    Journal: Biomaterials Research

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    doi: 10.34133/bmr.0320

    Figure Lengend Snippet: Schematic illustration of the protein-based platform for the direct osteogenic reprogramming of human dermal fibroblasts (HDFs). (A) Production of recombinant Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. Expression plasmids encoding reprogramming factors fused with the 30Kc19 moiety were introduced into an E. coli expression system to generate cell-permeable recombinant proteins. (B) Direct osteogenic reprogramming via intracellular protein transduction. The fusion proteins are intracellularly delivered through 30Kc19-mediated transport. Oct4-30Kc19 induces a state of cellular plasticity, while Cbfβ-30Kc19 promotes osteogenic lineage commitment, synergistically driving the conversion of HDFs into functional osteoblasts.

    Article Snippet: Primary human osteoblasts (hOBs; PromoCell, Heidelberg, Germany) were cultured in Osteoblast Growth Medium (PromoCell) according to the manufacturer’s instructions.

    Techniques: Recombinant, Expressing, Transduction, Functional Assay

    Direct reprogramming of HDFs into osteoblasts through ectopic overexpression of Oct4 and Cbfβ. (A) Schematic illustration of direct reprogramming process using the pCXLE episomal plasmid delivery system. The pCXLE-Oct4 and pCXLE-Cbfβ plasmids were delivered into HDFs via cationic polymer-based transfection, either individually or in combination. (B) Representative images of alkaline phosphatase (ALP) staining after 14 d of culture in osteogenic medium (OM). (C and D) Calcium deposition after 24 d of osteogenic induction, as detected by Alizarin Red S (ARS) and OsteoImage assays. (E and F) Immunofluorescence images showing expression of osteopontin (OPN) and osteocalcin (OCN), on day 24. Coexpression of Oct4 and Cbfβ induced robust expression of both osteogenic markers.

    Journal: Biomaterials Research

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    doi: 10.34133/bmr.0320

    Figure Lengend Snippet: Direct reprogramming of HDFs into osteoblasts through ectopic overexpression of Oct4 and Cbfβ. (A) Schematic illustration of direct reprogramming process using the pCXLE episomal plasmid delivery system. The pCXLE-Oct4 and pCXLE-Cbfβ plasmids were delivered into HDFs via cationic polymer-based transfection, either individually or in combination. (B) Representative images of alkaline phosphatase (ALP) staining after 14 d of culture in osteogenic medium (OM). (C and D) Calcium deposition after 24 d of osteogenic induction, as detected by Alizarin Red S (ARS) and OsteoImage assays. (E and F) Immunofluorescence images showing expression of osteopontin (OPN) and osteocalcin (OCN), on day 24. Coexpression of Oct4 and Cbfβ induced robust expression of both osteogenic markers.

    Article Snippet: Primary human osteoblasts (hOBs; PromoCell, Heidelberg, Germany) were cultured in Osteoblast Growth Medium (PromoCell) according to the manufacturer’s instructions.

    Techniques: Over Expression, Plasmid Preparation, Polymer, Transfection, Staining, Immunofluorescence, Expressing

    Direct reprogramming of HDFs into osteoblasts using cell-permeable protein-based platform. (A) Schematic illustration of the reprogramming strategy using 30Kc19-fused recombinant proteins. HDFs were treated with a combination of Oct4-30Kc19 and Cbfβ-30Kc19 recombinant proteins 8 times over 8 d, followed by culture in OM. (B and C) ARS staining and subsequent quantification on day 24, showing robust calcium deposition in the group treated with both proteins. Data are presented as means ± SD ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. Unless otherwise indicated, comparisons were made to the nontreated control group (** P < 0.01; *** P < 0.001; ns, not significant). (D and E) Von Kossa staining and OsteoImage mineralization assay images, confirming mineralized matrix formation. Treatment with both Oct4-30Kc19 and Cbfβ-30Kc19 resulted in significantly enhanced mineralization compared with single-factor or untreated controls.

    Journal: Biomaterials Research

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    doi: 10.34133/bmr.0320

    Figure Lengend Snippet: Direct reprogramming of HDFs into osteoblasts using cell-permeable protein-based platform. (A) Schematic illustration of the reprogramming strategy using 30Kc19-fused recombinant proteins. HDFs were treated with a combination of Oct4-30Kc19 and Cbfβ-30Kc19 recombinant proteins 8 times over 8 d, followed by culture in OM. (B and C) ARS staining and subsequent quantification on day 24, showing robust calcium deposition in the group treated with both proteins. Data are presented as means ± SD ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. Unless otherwise indicated, comparisons were made to the nontreated control group (** P < 0.01; *** P < 0.001; ns, not significant). (D and E) Von Kossa staining and OsteoImage mineralization assay images, confirming mineralized matrix formation. Treatment with both Oct4-30Kc19 and Cbfβ-30Kc19 resulted in significantly enhanced mineralization compared with single-factor or untreated controls.

    Article Snippet: Primary human osteoblasts (hOBs; PromoCell, Heidelberg, Germany) were cultured in Osteoblast Growth Medium (PromoCell) according to the manufacturer’s instructions.

    Techniques: Recombinant, Staining, Control, Mineralization Assay

    Transcriptomic remodeling toward an osteoblast lineage by Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. (A) Scatterplot showing differentially expressed genes (DEGs) between nontreated HDFs and protein-induced osteoblasts (piOBs) treated with Oct4-30Kc19 and Cbfβ-30Kc19 proteins (fold change ≥ 2). (B) Gene Ontology (GO) enrichment analysis of DEGs, highlighting overrepresentation of transcription-related biological processes. (C) Protein interaction network of enriched GO terms related to transcription regulation by RNA polymerase II. (D) Hierarchical clustering analysis of genes differentially expressed in both piOBs and primary human osteoblasts (hOBs), relative to HDFs. (E) Heatmap of DEGs associated with the ossification GO term, showing the expression of key osteogenic markers.

    Journal: Biomaterials Research

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    doi: 10.34133/bmr.0320

    Figure Lengend Snippet: Transcriptomic remodeling toward an osteoblast lineage by Oct4-30Kc19 and Cbfβ-30Kc19 fusion proteins. (A) Scatterplot showing differentially expressed genes (DEGs) between nontreated HDFs and protein-induced osteoblasts (piOBs) treated with Oct4-30Kc19 and Cbfβ-30Kc19 proteins (fold change ≥ 2). (B) Gene Ontology (GO) enrichment analysis of DEGs, highlighting overrepresentation of transcription-related biological processes. (C) Protein interaction network of enriched GO terms related to transcription regulation by RNA polymerase II. (D) Hierarchical clustering analysis of genes differentially expressed in both piOBs and primary human osteoblasts (hOBs), relative to HDFs. (E) Heatmap of DEGs associated with the ossification GO term, showing the expression of key osteogenic markers.

    Article Snippet: Primary human osteoblasts (hOBs; PromoCell, Heidelberg, Germany) were cultured in Osteoblast Growth Medium (PromoCell) according to the manufacturer’s instructions.

    Techniques: Expressing

    Efficient bone defect regeneration using a cell-permeable protein-based direct reprogramming platform. (A) Schematic illustration of the in vivo bone regeneration experiment. HDFs were pretreated 8 times with Oct4-30Kc19 and Cbfβ-30Kc19 proteins, seeded onto gelatin cryogels, and transplanted into 4-mm-sized calvarial defects in mice. Created with biorender.com . (B) Representative micro-CT 3D images showing bone regeneration 8 weeks post-transplantation. Green areas and arrows indicate newly regenerated bones, while yellow arrows denote bone defect regions. (C and D) Quantification of bone volume fraction (BV/TV) and trabecular separation in the regenerated bone tissue. Data are presented as means ± SD ( n = 4). Statistical significance was determined by Student’s t test (*** P < 0.001). (E) Hematoxylin and eosin (H&E) staining showing histological differences between defects implanted with untreated HDFs and those implanted with piOBs. (F) Masson’s trichrome (MTC) staining revealing collagen-rich new bone formation in the piOB-treated group. FT, fibrous tissues; NB, new bones. (G and H) Immunofluorescent staining for OPN and OCN, confirming the presence of mature osteoblast-derived matrix in piOB-transplanted defects.

    Journal: Biomaterials Research

    Article Title: Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins

    doi: 10.34133/bmr.0320

    Figure Lengend Snippet: Efficient bone defect regeneration using a cell-permeable protein-based direct reprogramming platform. (A) Schematic illustration of the in vivo bone regeneration experiment. HDFs were pretreated 8 times with Oct4-30Kc19 and Cbfβ-30Kc19 proteins, seeded onto gelatin cryogels, and transplanted into 4-mm-sized calvarial defects in mice. Created with biorender.com . (B) Representative micro-CT 3D images showing bone regeneration 8 weeks post-transplantation. Green areas and arrows indicate newly regenerated bones, while yellow arrows denote bone defect regions. (C and D) Quantification of bone volume fraction (BV/TV) and trabecular separation in the regenerated bone tissue. Data are presented as means ± SD ( n = 4). Statistical significance was determined by Student’s t test (*** P < 0.001). (E) Hematoxylin and eosin (H&E) staining showing histological differences between defects implanted with untreated HDFs and those implanted with piOBs. (F) Masson’s trichrome (MTC) staining revealing collagen-rich new bone formation in the piOB-treated group. FT, fibrous tissues; NB, new bones. (G and H) Immunofluorescent staining for OPN and OCN, confirming the presence of mature osteoblast-derived matrix in piOB-transplanted defects.

    Article Snippet: Primary human osteoblasts (hOBs; PromoCell, Heidelberg, Germany) were cultured in Osteoblast Growth Medium (PromoCell) according to the manufacturer’s instructions.

    Techniques: In Vivo, Micro-CT, Transplantation Assay, Staining, Derivative Assay

    Glucocorticoids impair osteoblast function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.

    Journal: Advanced Healthcare Materials

    Article Title: Ascorbic Acid Modulates Collagen Properties in Glucocorticoid‐Induced Osteoporotic Bone: Insights into Chemical, Mechanical, and Biological Regulation

    doi: 10.1002/adhm.202502606

    Figure Lengend Snippet: Glucocorticoids impair osteoblast function and collagen expression in vivo. A) H&E staining of mouse bone after 60 days without (Veh) or with the GC, prednisolone (Psl); Scale bar: 1000 µm. B) Representative images for Alkaline phosphatase (ALP) staining of mouse bones; Scale bar, 400 µm; Magnification: Scale bar, 100 µm. C) Quantitative analysis of the ALP‐positive surface intensity in bone tissue sections for n = 5 mice. D) Representative images for Verhoeff van Geison staining showing general elastin‐ (black) and collagen‐specific proteins (red) of mouse bones; Scale bar, 400 µm; Magnification: Scale bar: 100 µm. E) Semi‐quantitative analysis of the collagen fibers‐positive surface intensity in bone tissue sections; n = 5 mice. F) Representative image of collagen type I alpha I (COL1A1) staining of bone sections. Yellow arrows indicate COL1A1 protein expression (red). Green diamonds indicate the interior of cortical bone, near the bone marrow. Scale bar, 50 µm. G) Graph showing the COL1A1 protein expression levels (artificial units; A.U.) in control and Psl‐treated bone tissues. H) Metabolomics KEGG visualization of in vitro osteo‐spheroids treated without (Veh) and with Psl at 100 µm for 7 d. I,J) Analysis of collagen‐related putative metabolites after significance analysis using Metaboanalyst only reported fold‐changes with p‐value < 0.05. Data are expressed as mean ± SD. N = 5, n = 3; significant differences: * p‐value < 0.05.

    Article Snippet: Human osteoblasts (HOBs) (PromoCell) were cultured in osteoblast growth medium (GM) (PromoCell) and differentiated in osteoblast mineralization medium (MM) (PromoCell).

    Techniques: Expressing, In Vivo, Staining, Control, In Vitro

    AA enhances COL1A1 biological activity and restores osteoblast function and COL1A1 regulation in the presence of Psl. A) ALP staining (red) of osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with (+AA), and in the Psl presence (+Psl) or absence (–Psl); Scale bar: 300 µm. B) Quantification of Mean Intensity of ALP (A.U.). C) Alzarin Red (AR) activity assay of osteo‐spheroids after 7 d with or without additional AA. Scale bar, 400 µm. D) Graph showing quantification of Mean Intensity of AR (A.U.). E) OsteoImaging mineralization assay quantifications of Mean Intensity (A.U.) of osteo‐spheroids incubated with or without additional AA for 7 d. F) Gene expression analysis of osteogenic markers ( BGLAP, DMP1, DLX3, RUNX2 ) of osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with (+AA), and in the Psl presence (+Psl) or absence (–Psl); Heatmap demonstrates the ∆CT averages. G) Gene expression analysis of COL1A1‐related genes ( PLOD1, PLOD3, DLX3, P3H1, P3H2, P3H3, LOX, SVCT2, COL1A2, COL22A1, IBSP, P4HA2, P4HA3, IFITM5 ) in osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with or without ascorbic acid (AA), and in the presence (+Psl) or absence (–Psl) of prednisolone (Psl); Heatmap demonstrates the ∆CT averages H) Fold change of top collagen‐related putative metabolites elevated in the presence of endogenous ascorbic acid (+AA) within the 3D matrix of osteo‐spheroids after 7 d of Psl (+Psl) treatment, based on untargeted metabolomics analysis; fold change threshold > 2 with significance; FDR p‐value < 0.05. The data are expressed as mean ± SD; N = 3, n = 3; significant differences: * * p‐value < 0.01; *** p‐value < 0.005 ; **** p‐value < 0.0001.

    Journal: Advanced Healthcare Materials

    Article Title: Ascorbic Acid Modulates Collagen Properties in Glucocorticoid‐Induced Osteoporotic Bone: Insights into Chemical, Mechanical, and Biological Regulation

    doi: 10.1002/adhm.202502606

    Figure Lengend Snippet: AA enhances COL1A1 biological activity and restores osteoblast function and COL1A1 regulation in the presence of Psl. A) ALP staining (red) of osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with (+AA), and in the Psl presence (+Psl) or absence (–Psl); Scale bar: 300 µm. B) Quantification of Mean Intensity of ALP (A.U.). C) Alzarin Red (AR) activity assay of osteo‐spheroids after 7 d with or without additional AA. Scale bar, 400 µm. D) Graph showing quantification of Mean Intensity of AR (A.U.). E) OsteoImaging mineralization assay quantifications of Mean Intensity (A.U.) of osteo‐spheroids incubated with or without additional AA for 7 d. F) Gene expression analysis of osteogenic markers ( BGLAP, DMP1, DLX3, RUNX2 ) of osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with (+AA), and in the Psl presence (+Psl) or absence (–Psl); Heatmap demonstrates the ∆CT averages. G) Gene expression analysis of COL1A1‐related genes ( PLOD1, PLOD3, DLX3, P3H1, P3H2, P3H3, LOX, SVCT2, COL1A2, COL22A1, IBSP, P4HA2, P4HA3, IFITM5 ) in osteo‐spheroids embedded in COL1A1 matrices, cultured for 7 d with or without ascorbic acid (AA), and in the presence (+Psl) or absence (–Psl) of prednisolone (Psl); Heatmap demonstrates the ∆CT averages H) Fold change of top collagen‐related putative metabolites elevated in the presence of endogenous ascorbic acid (+AA) within the 3D matrix of osteo‐spheroids after 7 d of Psl (+Psl) treatment, based on untargeted metabolomics analysis; fold change threshold > 2 with significance; FDR p‐value < 0.05. The data are expressed as mean ± SD; N = 3, n = 3; significant differences: * * p‐value < 0.01; *** p‐value < 0.005 ; **** p‐value < 0.0001.

    Article Snippet: Human osteoblasts (HOBs) (PromoCell) were cultured in osteoblast growth medium (GM) (PromoCell) and differentiated in osteoblast mineralization medium (MM) (PromoCell).

    Techniques: Activity Assay, Staining, Cell Culture, Mineralization Assay, Incubation, Gene Expression